Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Baxter
Johnson and Johnson
Merck
McKesson

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,071,648

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,071,648 protect, and when does it expire?

Patent 8,071,648 protects NEVANAC and is included in one NDA.

This patent has twenty-six patent family members in twenty-two countries.

Summary for Patent: 8,071,648
Title:Topical nepafenac formulations
Abstract: Topical suspension compositions of nepafenac are disclosed. The compositions are especially suitable for topical ophthalmic administration.
Inventor(s): Wong; Warren (Fort Worth, TX)
Assignee: Novartis AG (Basel, CH)
Application Number:12/888,631
Patent Claim Types:
see list of patent claims
Composition;

Drugs Protected by US Patent 8,071,648

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis Pharms Corp NEVANAC nepafenac SUSPENSION/DROPS;OPHTHALMIC 021862-001 Aug 19, 2005 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,071,648

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 052252   Start Trial
Austria 476200   Start Trial
Australia 2005311738   Start Trial
Brazil PI0518904   Start Trial
Canada 2586807   Start Trial
China 101068573   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Baxter
McKinsey
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.